- Investor's Business Daily•26 days ago
Paratek, Cyclacel and Benitec stocks led a biotech surge on Tuesday, rising on strong trial results.
- Motley Fool•26 days ago
The company announced preclinical data supporting its gene replacement therapy in a rare muscle disease.
- PR Newswire•26 days ago
Key pre-clinical data on oculopharyngeal muscular dystrophy (OPMD) published in Nature Communications
NASDAQ: BNTCW) is pleased to announce that the initial pre-clinical efficacy results of the OPMD program have been published in Nature Communications, an open access scientific journal published by the Nature Publishing Group. OPMD, a rare progressive muscle-wasting disease caused by mutation in the poly(A)-binding protein nuclear 1 (PABPN1) gene, is characterised by eyelid drooping, swallowing difficulties, and proximal limb weakness.
BLT.AX : Summary for BENITEC FPO - Yahoo Finance
Benitec Biopharma Limited (BLT.AX)
ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
|Day's Range||0.18 - 0.19|
|52 Week Range||0.09 - 0.28|
|PE Ratio (TTM)||-2.34|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|